6-K: Zantac (Ranitidine) Litigation - Kimbrow Case
6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease
6-K: Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Gsk and Curevac to Restructure Collaboration into New Licensing Agreement
6-K: Total Voting Rights and Capital
6-K: Zantac (Ranitidine) Litigation - Gross Case
6-K: Jemperli Plus Chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer
6-K: Gsk's Omjjara Approved in Japan for Treatment of Myelofibrosis
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Gsk Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation
6-K: Gsk Fails to Reach Settlement in Zantac Case and Will Continue with Appeal
6-K: FDA Approves Expansion of Glaxosmithkline Rsv Vaccine to Adults 50 to 59 Years of Age
6-K: Total Voting Rights and Capital
6-K: Jemperli (Dostarlimab) Trial Continues to Show Unprecedented Results with No Evidence of Disease in 100% of Patients with Locally Advanced Mismatch Repair Deficient (Dmmr) Rectal Cancer
6-K: Blenrep Combination Reduced the Risk of Disease Progression or Death by Nearly 50% Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma
No Data